Download Library

 
 
 
Download Library
Document Type
Scientific Committee Charter
PDF
155.3 KB
AGM 2017 Presentation
PDF
1.4 MB
Genmab 2016 Annual Report
pdf
8.7 MB
Full Year 2016 Results Presentation
PDF
488.8 KB
Corporate Governance Report 2016 - English
PDF
332.4 KB
CSR Report 2016
PDF
274.2 KB
Investor Fact Sheet
PDF
253.1 KB
Full Year 2016 Results Podcast
MP3
28.2 MB
35th Annual J.P. Morgan Healthcare Conference, San Francisco, CA, US - January 2017
PDF
1.2 MB
Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone Alone for Relapsed or Refractory Multiple Myeloma Based on Prior Treatment Exposure: Updated Efficacy Analysis of CASTOR - ASH Poster - December 2016 (Chanan-Khan)
PDF
470.6 KB
Use of Montelukast to Reduce Infusion Reactions in an Early Access Program (EAP) of Daratumumab in United States Patients With Relapsed or Refractory Multiple Myeloma - ASH Poster - December 2016 (Chari)
PDF
545.4 KB
Genmab's ASH 2016 Data Review Meeting, San Diego, CA - December 2016
PDF
3.3 MB
Cost-effective Analysis of Ofatumumab for Relapsed CLL - ASH poster - December 2016 (Tremblay)
PDF
279.5 KB
High-Parameter Mass Cytometry Evaluation of Relapsed/Refractory MM Pts Treated with Daratumumab Supports Immune Modulation As a Novel Mechanism of Action - ASH poster - December 2016 (Adams)
PDF
4.9 MB
DRd Induces Clonality Increase and T-Cell Expansion: Results from a Phase 3 Randomized Study (POLLUX) - ASH poster - December 2016 (Chiu)
PDF
888.9 KB
Adjusted Comparisons Suggest Daratumumab Is Associated with Prolonged Survival Compared with Standard of Care in pts with Heavily Pre-Treated & Highly Refractory MM - ASH poster - December 2016 (Kumar)
PDF
530.3 KB
Phase 1b Study to Assess Subcutaneous Daratumumab in pts with Relapsed or Refractory MM (PAVO) - ASH presentation - December 2016 (Usmani)
PDF
981.3 KB
Efficacy of DVd Versus Vd in Relapsed or Refractory Myeloma Based on Prior Lines of Therapy: Updated Analysis of Castor - ASH presentation - December 2016 (Mateos)
PDF
1.3 MB
Efficacy of DRd Versus Rd in Relapsed or Refractory MM Patients with 1 to 3 Prior Lines of Therapy: Updated Analysis of Pollux - ASH presentation - December 2016 (Usmani)
PDF
1.4 MB
Population Pharmacokinetic and Exposure-Response Analyses for Daratumumab in Combination Therapies for Patients with MM Who Have Received 1 or More Prior Lines of Therapy - ASH poster - December 2016 (Xu)
PDF
237.7 KB
Comparative Effectiveness of Daratumumab Versus a Real-World Historical Control in Heavily Pretreated and Highly Refractory MM - ASH poster - December 2016 (Hájek)
PDF
308.5 KB
Efficacy of DRd Versus Rd for Relapsed or Refractory MM: Updated Analysis of Pollux - ASH presentation - December 2016 (Moreau)
PDF
1.0 MB
Evaluation of MRD in Relapsed/Refractory MM Patients Treated with Daratumumab in Combination with Rd or Vd - ASH presentation - December 2016 (Avet-Loiseau)
PDF
2.6 MB

Page: First Previous
1
2
3
4
5
6
7
8
...
19
Next Last

 
 
 

Please be advised that additional documents and media, such as fact sheets and conference call webcasts, are available only in English and can be accessed by clicking on the English tab.

 

Download Library
Document Type
Kvartalsrapport 3. kvartal 2001
PDF
161.0 KB
Halvårsrapport Første halvår 2001
PDF
147.7 KB
Kvartalsrapport 1.kvartal 2001
PDF
145.0 KB
Årsregnskab 2001
PDF
429.6 KB
Kvartalsrapport - 3. kvartal 2000
PDF
59.2 KB
Årsregnskab 2000
PDF
592.8 KB
Page: First Previous
1
2
3
4